The Queen's Medical Center Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2009
NCT00928252
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

The Queen's Medical Center

Active Ingredients

Drugs in Phase 3 Trials (1)

tocilizumab (actemra) (1 trial)

Drugs in Phase 2 Trials (2)

fluorocholine (2 trials)

fluoromethylcholine (18f) (FCH) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Liver Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 3